source
- FDA details flexibilities for new cell and gene therapies to leverage past dataThe FDA is further explaining to cell and gene therapy developers the types of prior knowledge companies can leverage for clinical, nonclinical and manufacturing-related work, according to new CBER…Endpoints · 1mo ago↗ source
- Anti-aging biotech NewLimit raises $435M at $3B+ valuationThe Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said Tues…Endpoints · 1mo ago↗ source
- STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trialLongevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.